Clinical implication of peritoneal cytology in the pancreatic cancer patients who underwent curative resection followed by adjuvant gemcitabine or S-1 chemotherapy.

Abstract

BACKGROUND/AIMS:

The clinical implications of peritoneal lavage cytology (CY) status in the patients who received curative resection and adjuvant chemotherapy have not been established.

METHODOLOGY:

We retrospectively analyzed clinical data from 143 consecutive patients who underwent macroscopically curative resection and received adjuvant gemcitabine or S-1 chemotherapy for pancreatic cancer from 2005 to 2014 in our institution. Correlations between CY status and survival and clinicopathological features were investigated.

RESULTS:

Of the 143 patients, 21 patients were peritoneal washing cytology positive (CY+) (14.7%). Although significant difference was observed in the tumor size, no other correlation between cytology status and clinicopathological parameter existed. The recurrence free survival (RFS) rates at 3 and 5 years after surgery were 5.1% and 0% in CY+ patients, respectively, and were 21.5% and 16.1% in peritoneal washing cytology negative (CY-) patients, respectively, which were significantly different (p=0.001). The OS rates at 3 and 5 years after surgery were 17.1% and 8.6% in CY+ patients, respectively, and were 26.1% and 16.1% in CY- patients, respectively, which were trend to worse in the CY+ patients (p=0.254).

CONCLUSION:

The patients with CY+ are likely to experience recurrence, even after they received curative resection and adjuvant Gemcitabine or S-1 adjuvant chemotherapy.

• Authors: Toru Aoyama, Yusuke Katayama, Masaaki Murakawa, Manabu Shiozawa, Manabu Morimoto, Naoto Yamamoto, Takaki Yoshikawa, Yasushi Rino, Munetaka Masuda, Soichiro Morinaga
• Journal: Hepato-gastroenterology (Hepatogastroenterology) 2015 Jan-Feb Vol. 62 Issue 137 Pg. 200-6 ISSN: 0172-6390 [Print] Greece
• PMID: 25911897 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antimetabolites, Antineoplastic
• Drug Combinations
• Deoxycytidine
• S 1 (combination)
• Tegafur
• Oxonic Acid
• Gemcitabine

Topics

• Adult
• Aged
• Aged, 80 and over
• Antimetabolites, Antineoplastic (administration & dosage, adverse effects)
• Chemotherapy, Adjuvant
• Deoxycytidine (administration & dosage, adverse effects, analogs & derivatives)
• Disease-Free Survival
• Drug Administration Schedule
• Drug Combinations
• Female
• Humans
• Japan
• Kaplan-Meier Estimate
• Male
• Middle Aged
• Neoplasm Recurrence, Local
• Oxonic Acid (administration & dosage, adverse effects)
• Pancreatectomy (adverse effects, mortality)
• Pancreatic Neoplasms (mortality, pathology, therapy)
• Papanicolaou Test
• Peritoneal Cavity (pathology)
• Peritoneal Lavage
• Predictive Value of Tests
• Proportional Hazards Models
• Retrospective Studies
• Risk Factors
• Tegafur (administration & dosage, adverse effects)
• Time Factors
• Treatment Outcome
• Tumor Burden
• Gemcitabine